Clinical Trials

(Breast Cancer)

Phase III Trial of LHRH Analog Administration during Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer

Cytogenetic and Fluorescence In Situ Hybridization Studies in Multiple Myeloma

A Phase II Surgical Trial of Intralesional Resection of Low-Grade Intracompartmental Chondrosarcoma of Bone

Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab, or Rituximab and G3139 Phosphorothioate Oligonucleotide (BCL-2 Antisense) Therapy for Young Adult Patients (< Age 60) with Advanced Stage Diffuse Large B-Cell NHL of Low and Low-Intermediate IPI Risk, Phase II

Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin’s Lymphoma

Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men

Neoadjuvant Chemoradiation Therapy with Oxaliplatin and Capecitabine for Patients with Surgically Resectable Gastric Cancer: A Pilot Phase II Trial with Molecular Correlates

A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment

A Phase II Study of Goserelin Plus Anastrozole as First Line Treatment in Male Patients With Hormone-Receptor Positive Metastatic or Recurrent Breast Cancer

Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab in Advanced, Poor Prognosis Carcinoid Patients

Phase II Trial of Pemetrexed in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC)

Temp Clos 6/22/10
A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia

Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab with or
without Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX or XELOX

Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer

A Phase II Trial of the Combination of OSI-774 (Erlotinib) and Bevacizumab (RhuMAb VEGF) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features (AdenoBAC)

A Prospective Observational Multicenter Cohort Study to Assess The Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment

A Phase II Trial of Azacitidine Plus Gemtuzumab Ozogamicin as Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia

A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/Erlotinib or Erlotinib Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with Performance Status 2 Selected by Serum Proteomics

A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in
Pre-Operative Therapy of Rectal Cancer

Randomized Placebo-Controlled Trial of Acetyl L-Carnitine for the Prevention of Taxane Induced Neuropathy

Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients with STAGE I Non-Small Cell Lung Cancer (NSCLC)

A Phase II Trial of mTOR Inhibitor, Everolimus (RAD001; NSC-733504), in Malignant Pleural Mesothelioma (MPM)

A Randomized Phase III Trial of CC-5013 (Lenalidomide) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously
Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant

A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) With or Without Bevacizumab, Either Preceded by or Followed by Every Two Week Doxorubicin (A) and Cyclophosphamide (C) Plus Pegfilgrastim PEG-G) As Neoadjuvant Therapy for Inflammatory and Locally Advanced
Her-2/Neu Negative Breast Cancer

A Phase II Study of Iodine-131-Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab Therapy for Patients With Advanced Stage Follicular Non-Hodgkin’s Lymphoma